SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

another SGLT2 inhibitor, in HFpEF. Both trials showed significant improvements in their primary outcome: Cardiovascular death or hospitalization for heart failure. The DELIVER trial’s outcome ...

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

A drug already used to treat people who have diabetes and/or chronic kidney disease could have added heart disease benefits, ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...